{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:21:21Z","timestamp":1790832081760,"version":"4.1.0"},"reference-count":132,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T00:00:00Z","timestamp":1641340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Duchenne muscular dystrophy (DMD) is an X-linked recessive, infancy-onset neuromuscular disorder characterized by progressive muscle weakness and atrophy, leading to delay of motor milestones, loss of autonomous ambulation, respiratory failure, cardiomyopathy, and premature death. DMD originates from mutations in the <jats:italic>DMD<\/jats:italic> gene that result in a complete absence of dystrophin. Dystrophin is a cytoskeletal protein which belongs to the dystrophin-associated protein complex, involved in cellular signaling and myofiber membrane stabilization. To date, the few available therapeutic options are aimed at lessening disease progression, but persistent loss of muscle tissue and function and premature death are unavoidable. In this scenario, one of the most promising therapeutic strategies for DMD is represented by adeno-associated virus (AAV)-mediated gene therapy. DMD gene therapy relies on the administration of exogenous micro-dystrophin, a miniature version of the dystrophin gene lacking unnecessary domains and encoding a truncated, but functional, dystrophin protein. Limited transgene persistence represents one of the most significant issues that jeopardize the translatability of DMD gene replacement strategies from the bench to the bedside. Here, we critically review preclinical and clinical studies of AAV-mediated gene therapy in DMD, focusing on long-term transgene persistence in transduced tissues, which can deeply affect effectiveness and sustainability of gene replacement in DMD. We also discuss the role played by the overactivation of the immune host system in limiting long-term expression of genetic material. In this perspective, further studies aimed at better elucidating the need for immune suppression in AAV-treated subjects are warranted in order to allow for life-long therapy in DMD patients.<\/jats:p>","DOI":"10.3389\/fneur.2021.814174","type":"journal-article","created":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T07:57:09Z","timestamp":1641369429000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":64,"title":["Adeno-Associated Virus (AAV)-Mediated Gene Therapy for Duchenne Muscular Dystrophy: The Issue of Transgene Persistence"],"prefix":"10.3389","volume":"12","author":[{"given":"Arianna","family":"Manini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Abati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andi","family":"Nuredini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Corti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo Pietro","family":"Comi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.10\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nat Rev Dis Prim."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1016\/S0140-6736(19)32910-1","article-title":"Muscular dystrophies","volume":"394","author":"Mercuri","year":"2019","journal-title":"Lancet."},{"key":"B3","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s13023-021-01862-w","article-title":"The clinical course of Duchenne muscular dystrophy in the corticosteroid treatment era: a systematic literature review","volume":"16","author":"Szabo","year":"2021","journal-title":"Orphanet J Rare Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.rehab.2013.06.002","article-title":"Evolution of life expectancy of patients with Duchenne muscular dystrophy at AFM Yolaine de Kepper centre between 1981 and 2011","volume":"56","author":"Kieny","year":"2013","journal-title":"Ann Phys Rehabil Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/dmcn.12922","article-title":"Neurodevelopmental, emotional, and behavioural problems in Duchenne muscular dystrophy in relation to underlying dystrophin gene mutations","volume":"58","author":"Ricotti","year":"2016","journal-title":"Dev Med Child Neurol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/ng0295-184","article-title":"The human dystrophin gene requires 16 hours to be transcribed and is cotranscriptionally spliced","volume":"9","author":"Tennyson","year":"1995","journal-title":"Nat Genet."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1007\/s00415-011-5979-z","article-title":"Genotype and phenotype characterization in a large dystrophinopathic cohort with extended follow-up","volume":"258","author":"Magri","year":"2011","journal-title":"J Neurol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/brain\/117.1.1-a","article-title":"Clinical variability in becker muscular dystrophy genetic, biochemical and immunohistochemical correlates","volume":"117","author":"Comi","year":"1994","journal-title":"Brain."},{"key":"B9","first-page":"172","article-title":"Current and emerging therapies in Becker muscular dystrophy (BMD)","volume":"38","author":"Angelini","year":"2019","journal-title":"Acta Myol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/0092-8674(87)90504-6","article-title":"Complete cloning of the duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals","volume":"50","author":"Koenig","year":"1987","journal-title":"Cell."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1002\/cphy.c140048","article-title":"The dystrophin complex: Structure, function, and implications for therapy","volume":"5","author":"Gao","year":"2015","journal-title":"Compr Physiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/335735a0","article-title":"Increased protein degradation results from elevated free calcium levels found in muscle from mdx mice","volume":"335","author":"Turner","year":"1988","journal-title":"Nature."},{"key":"B13","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/nm1736","article-title":"Genetic and pharmacologic inhibition of mitochondrial-dependent necrosis attenuates muscular dystrophy","volume":"14","author":"Millay","year":"2008","journal-title":"Nat Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/352536a0","article-title":"The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy","volume":"352","author":"Stedman","year":"1991","journal-title":"Nature."},{"key":"B15","doi-asserted-by":"publisher","first-page":"13818","DOI":"10.1073\/pnas.250379497","article-title":"Functional muscle ischemia in neuronal nitric oxide synthase-deficient skeletal muscle of children with Duchenne muscular dystrophy","volume":"97","author":"Sander","year":"2000","journal-title":"Proc Natl Acad Sci USA."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10974-012-9330-9","article-title":"Contribution of oxidative stress to pathology in diaphragm and limb muscles with Duchenne muscular dystrophy","volume":"34","author":"Kim","year":"2013","journal-title":"J Muscle Res Cell Motil."},{"key":"B17","doi-asserted-by":"publisher","first-page":"299rv4","DOI":"10.1126\/scitranslmed.aaa7322","article-title":"Immune-mediated pathology in Duchenne muscular dystrophy","volume":"7","author":"Rosenberg","year":"2015","journal-title":"Sci Transl Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"CD003725","DOI":"10.1002\/14651858.CD003725.pub4","article-title":"Corticosteroids for the treatment of Duchenne muscular dystrophy","volume":"2016","author":"Matthews","year":"2016","journal-title":"Cochrane Database Syst Rev."},{"key":"B19","doi-asserted-by":"publisher","first-page":"18168","DOI":"10.3390\/molecules201018168","article-title":"Duchenne muscular dystrophy: from diagnosis to therapy","volume":"20","author":"Falzarano","year":"2015","journal-title":"Molecules."},{"key":"B20","unstructured":"KYMRIAH (tisagenlecleucel)"},{"key":"B21","year":"","journal-title":"FDA Approves Novel Gene Therapy to Treat Patients With a Rare Form of Inherited Vision Loss"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s40265-019-01162-5","article-title":"Onasemnogene abeparvovec: first global approval","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs."},{"key":"B23","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1080\/14728222.2020.1738390","article-title":"Silence superoxide dismutase 1 (SOD1): a promising therapeutic target for amyotrophic lateral sclerosis (ALS)","volume":"24","author":"Abati","year":"2020","journal-title":"Expert Opin Ther Targets."},{"key":"B24","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1126\/science.149.3685.754","article-title":"Adenovirus-associated defective virus particles","volume":"149","author":"Atchison","year":"1965","journal-title":"Science."},{"key":"B25","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.ymthe.2004.09.011","article-title":"Adeno-associated virus and the development of adeno-associated virus vectors: a historical perspective","volume":"10","author":"Carter","year":"2004","journal-title":"Mol Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1126\/science.aaw2900","article-title":"Comprehensive AAV capsid fitness landscape reveals a viral gene and enables machine-guided design","volume":"366","author":"Ogden","year":"2019","journal-title":"Science."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/advs.202004018","article-title":"Synthetic biology: emerging concepts to design and advance adeno-associated viral vectors for gene therapy","volume":"2004018","author":"Wagner","year":"2021","journal-title":"Adv Sci."},{"key":"B28","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1073\/pnas.73.3.742","article-title":"Concatemers of alternating plus and minus strands are intermediates in adenovirus associated virus DNA synthesis","volume":"73","author":"Straus","year":"1976","journal-title":"Proc Natl Acad Sci USA."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1128\/jvi.01968-07","article-title":"Complete in vitro reconstitution of adeno-associated virus DNA replication requires the minichromosome maintenance complex proteins","volume":"82","author":"Nash","year":"2008","journal-title":"J Virol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1128\/jvi.66.2.1119-1128.1992","article-title":"Partial purification of adeno-associated virus Rep78, Rep52, and Rep40 and their biochemical characterization","volume":"66","author":"Im","year":"1992","journal-title":"J Virol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S1046-2023(02)00228-1","article-title":"Adeno-associated virus vectors for gene transfer to the brain","volume":"28","author":"Okada","year":"2002","journal-title":"Methods."},{"key":"B32","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/BF02253246","article-title":"Adeno-associated virus-based vectors in gene therapy","volume":"7","author":"Tal","year":"2000","journal-title":"J Biomed Sci."},{"key":"B33","doi-asserted-by":"publisher","first-page":"11290","DOI":"10.1128\/jvi.00963-07","article-title":"Palindromes with a modest arm length of \u227320 base pairs are a significant target for recombinant adeno-associated virus vector integration in the liver, muscles, and heart in mice","volume":"81","author":"Inagaki","year":"2007","journal-title":"J Virol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1006\/bbrc.2001.5730","article-title":"Development and characterization of an antisense-mediated prepackaging cell line for adeno-associated virus vector production","volume":"288","author":"Okada","year":"2001","journal-title":"Biochem Biophys Res Commun."},{"key":"B35","doi-asserted-by":"crossref","DOI":"10.5772\/53023","article-title":"Efficient AAV vector production system: towards gene therapy for duchenne muscular dystrophy","volume-title":"Gene Therapy - Tools and Potential Applications","author":"Okada","year":""},{"key":"B36","first-page":"748","article-title":"Recombinant adeno-associated virus (AAV-CFTR) vectors do not integrate in a site-specific fashion in an immortalized epithelial cell line","volume":"3","author":"Kearns","year":"1996","journal-title":"Gene Ther."},{"key":"B37","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nbt1073","article-title":"Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart","volume":"23","author":"Wang","year":"2005","journal-title":"Nat Biotechnol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nbt.1515","article-title":"Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes","volume":"27","author":"Foust","year":"2009","journal-title":"Nat Biotechnol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N Engl J Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1161\/01.RES.0000237661.18885.f6","article-title":"Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo","volume":"99","author":"Pacak","year":"2006","journal-title":"Circ Res"},{"key":"B41","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/mt.2011.287","article-title":"The AAV vector toolkit: poised at the clinical crossroads","volume":"20","author":"Asokan","year":"2012","journal-title":"Mol Ther."},{"key":"B42","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1128\/jvi.77.6.3495-3504.2003","article-title":"Genetic fate of recombinant adeno-associated virus vector genomes in muscle","volume":"77","author":"Schnepp","year":"2003","journal-title":"J Virol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"9468","DOI":"10.1128\/jvi.73.11.9468-9477.1999","article-title":"Concatamerization of adeno-associated virus circular genomes occurs through intermolecular recombination","volume":"73","author":"Yang","year":"1999","journal-title":"J Virol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"8568","DOI":"10.1128\/jvi.72.11.8568-8577.1998","article-title":"Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue","volume":"72","author":"Duan","year":"1998","journal-title":"J Virol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"6969","DOI":"10.1128\/jvi.75.15.6969-6976.2001","article-title":"Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo","volume":"75","author":"Nakai","year":"2001","journal-title":"J Virol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/4743","article-title":"Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector","volume":"5","author":"Herzog","year":"1999","journal-title":"Nat Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1089\/hum.2017.025","article-title":"S\/MAR Element facilitates episomal long-term persistence of adeno-associated virus vector genomes in proliferating cells","volume":"28","author":"Hagedorn","year":"2017","journal-title":"Hum Gene Ther."},{"key":"B48","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1128\/JVI.03371-13","article-title":"Differential adeno-associated virus serotype-specific interaction patterns with synthetic heparins and other glycans","volume":"88","author":"Mietzsch","year":"2014","journal-title":"J Virol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/gt.2010.168","article-title":"Myocardial gene delivery using molecular cardiac surgery with recombinant adeno-associated virus vectors in vivo","volume":"18","author":"White","year":"2011","journal-title":"Gene Ther"},{"key":"B50","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/mt.2014.200","article-title":"A phase 1\/2a follistatin gene therapy trial for becker muscular dystrophy","volume":"23","author":"Mendell","year":"2015","journal-title":"Mol Ther."},{"key":"B51","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/4758","article-title":"Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2","volume":"5","author":"Qing","year":"1999","journal-title":"Nat Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1128\/JVI.79.1.609-614.2005","article-title":"Hepatocyte growth factor receptor is a coreceptor for adeno-associated virus type 2 infection","volume":"79","author":"Kashiwakura","year":"2005","journal-title":"J Virol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"9831","DOI":"10.1128\/JVI.00878-06","article-title":"The 37\/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9","volume":"80","author":"Akache","year":"2006","journal-title":"J Virol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/4768","article-title":"\u03b1V\u03b25 integrin: a co-receptor for adeno-associated virus type 2 infection","volume":"5","author":"Summerford","year":"1999","journal-title":"Nat Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"8961","DOI":"10.1128\/JVI.00843-06","article-title":"Adeno-associated virus type 2 contains an integrin \u03b15\u03b21 binding domain essential for viral cell entry","volume":"80","author":"Asokan","year":"2006","journal-title":"J Virol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1089\/hum.2010.075","article-title":"Human hepatocyte growth factor receptor is a cellular coreceptor for adeno-associated virus serotype 3","volume":"21","author":"Ling","year":"2010","journal-title":"Hum Gene Ther."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1038\/nm929","article-title":"Identification of PDGFR as a receptor for AAV-5 transduction","volume":"9","author":"Pasquale G","year":"2003","journal-title":"Nat Med."},{"key":"B58","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/nm.2145","article-title":"Epidermal growth factor receptor is a co-receptor for adeno-associated virus serotype 6","volume":"16","author":"Weller","year":"2010","journal-title":"Nat Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"13532","DOI":"10.1074\/jbc.M110.210922","article-title":"Terminal N-linked galactose is the primary receptor for adeno-associated virus 9","volume":"286","author":"Shen","year":"2011","journal-title":"J Biol Chem."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1001\/jamaneurol.2020.1484","article-title":"Assessment of systemic delivery of rAAVrh74MHCK7micro-dystrophin in children with duchenne muscular dystrophy","volume":"77","author":"Mendell","year":"2020","journal-title":"JAMA Neurol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1038\/sj.gt.3302766","article-title":"Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice","volume":"13","author":"Rivi\u00e8re","year":"2006","journal-title":"Gene Ther."},{"key":"B62","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.ymthe.2004.07.016","article-title":"Efficient transduction of skeletal muscle using vectors based on adeno-associated virus serotype 6","volume":"10","author":"Blankinship","year":"2004","journal-title":"Mol Ther."},{"key":"B63","doi-asserted-by":"publisher","first-page":"11854","DOI":"10.1073\/pnas.182412299","article-title":"Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy","volume":"99","author":"Gao","year":"2002","journal-title":"Proc Natl Acad Sci USA."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1038\/mt.2010.94","article-title":"Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs","volume":"18","author":"Kornegay","year":"2010","journal-title":"Mol Ther."},{"key":"B65","doi-asserted-by":"publisher","first-page":"76771","DOI":"10.1371\/journal.pone.0076771","article-title":"Hybrid adeno-associated viral vectors utilizing transposase-mediated somatic integration for stable transgene expression in human cells","volume":"8","author":"Zhang","year":"2013","journal-title":"PLoS ONE."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1038\/mt.2011.72","article-title":"Preclinical differences of intravascular aav9 delivery to neurons and glia: A comparative study of adult mice and nonhuman primates","volume":"19","author":"Gray","year":"2011","journal-title":"Mol Ther."},{"key":"B67","doi-asserted-by":"publisher","first-page":"e76310","DOI":"10.1371\/journal.pone.0076310","article-title":"Analysis of transduction efficiency, tropism and axonal transport of AAV serotypes 1, 2, 5, 6, 8 and 9 in the mouse brain","volume":"8","author":"Aschauer","year":"2013","journal-title":"PLoS ONE."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/mt.2009.71","article-title":"Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons","volume":"17","author":"Duque","year":"2009","journal-title":"Mol Ther."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1016\/j.ymthe.2020.07.009","article-title":"Broader implications of progressive liver dysfunction and lethal sepsis in two boys following systemic high-dose AAV","volume":"28","author":"Morales","year":"2020","journal-title":"Mol Ther."},{"key":"B70","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1089\/humc.2013.208","article-title":"Feasibility and safety of systemic rAAV9-h NAGLU delivery for treating mucopolysaccharidosis IIIB: toxicology, biodistribution, and immunological assessments in primates","volume":"25","author":"Murrey","year":"2014","journal-title":"Hum Gene Ther Clin Dev."},{"key":"B71","doi-asserted-by":"publisher","first-page":"4919","DOI":"10.1016\/j.cell.2021.08.028","article-title":"Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species","volume":"184","author":"Tabebordbar","year":"2021","journal-title":"Cell."},{"key":"B72","doi-asserted-by":"publisher","first-page":"E4812","DOI":"10.1073\/pnas.1704766114","article-title":"Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion","volume":"114","author":"Tse","year":"2017","journal-title":"Proc Natl Acad Sci USA."},{"key":"B73","doi-asserted-by":"publisher","first-page":"194ra92","DOI":"10.1126\/scitranslmed.3005795","article-title":"Overcoming preexisting humoral immunity to AAV using capsid decoys","volume":"5","author":"Mingozzi","year":"2013","journal-title":"Sci Transl Med."},{"key":"B74","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/mt.2013.244","article-title":"Plasmapheresis eliminates the negative impact of AAV antibodies on microdystrophin gene expression following vascular delivery","volume":"22","author":"Chicoine","year":"2014","journal-title":"Mol Ther."},{"key":"B75","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat Rev Drug Discov."},{"key":"B76","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ymthe.2019.12.010","article-title":"Vector immunogenicity in humans: a long journey to successful gene transfer","volume":"28","author":"Verdera","year":"2020","journal-title":"Mol Ther."},{"key":"B77","doi-asserted-by":"publisher","first-page":"S207","DOI":"10.1016\/j.nmd.2019.06.594","article-title":"O40Intrathecal administration of onasemnogene abeparvovec gene-replacement therapy (GRT) for spinal muscular atrophy type 2 (SMA2): phase 1\/2a study (STRONG)","volume":"29","author":"Finkel","year":"2019","journal-title":"Neuromuscul Disord."},{"key":"B78","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1089\/hum.2020.29133.bfs","article-title":"After third death, audentes' AT132 remains on clinical hold","volume":"31","author":"Philippidis","year":"2020","journal-title":"Hum Gene Ther."},{"key":"B79","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/ng0696-175","article-title":"gene mutated in X\u2013linked myotubular myopathy defines a new putative tyrosine phosphatase family conserved in yeast","volume":"13","author":"Laporte","year":"1996","journal-title":"Nat Genet."},{"key":"B80","article-title":"Pfizer Presents Initial Clinical Data on Phase 1b Gene Therapy Study for Duchenne Muscular Dystrophy (DMD)","year":""},{"key":"B81","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1016\/j.ymthe.2018.07.011","article-title":"Systemic AAV Micro-dystrophin gene therapy for duchenne muscular dystrophy","volume":"26","author":"Duan","year":"2018","journal-title":"Mol Ther."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1089\/hum.1995.6.11-1477","article-title":"Recombinant truncated dystrophin minigenes: construction, expression, and adenoviral delivery","volume":"6","author":"Clemens","year":"1995","journal-title":"Hum Gene Ther."},{"key":"B83","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/343180a0","article-title":"Very mild muscular dystrophy associated with the deletion of 46% of dystrophin","volume":"343","author":"England","year":"1990","journal-title":"Nature."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1089\/10430340260185085","article-title":"Adeno-associated virus vector-mediated minidystrophin gene therapy improves dystrophic muscle contractile function in mdx mice","volume":"13","author":"Watchko","year":"2002","journal-title":"Hum Gene Ther."},{"key":"B85","doi-asserted-by":"publisher","first-page":"13714","DOI":"10.1073\/pnas.240335297","article-title":"Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model","volume":"97","author":"Wang","year":"2000","journal-title":"Proc Natl Acad Sci USA."},{"key":"B86","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/nm1439","article-title":"rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice","volume":"12","author":"Gregorevic","year":"2006","journal-title":"Nat Med."},{"key":"B87","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1093\/hmg\/11.7.733","article-title":"Adeno-associated virus vector gene transfer and sarcolemmal expression of a 144 kDa micro-dystrophin effectively restores the dystrophin-associated protein complex and inhibits myofibre degeneration in nude\/mdx mice","volume":"11","author":"Fabb","year":"2002","journal-title":"Hum Mol Genet."},{"key":"B88","doi-asserted-by":"publisher","first-page":"3570","DOI":"10.1073\/pnas.93.8.3570","article-title":"Functional protection of dystrophic mouse (mdx) muscles after adenovirus-mediated transfer of a dystrophin minigene","volume":"93","author":"Deconinck","year":"1996","journal-title":"Proc Natl Acad Sci USA."},{"key":"B89","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/ng1093-130","article-title":"Long\u2013term correction of mouse dystrophic degeneration by adenovirus\u2013mediated transfer of a minidystrophin gene","volume":"5","author":"Vincent","year":"1993","journal-title":"Nat Genet."},{"key":"B90","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1089\/hum.1996.7.2-129","article-title":"Dystrophin expression in muscles of mdx mice after adenovirus-mediated in vivo gene transfer","volume":"7","author":"Acsadi","year":"1996","journal-title":"Hum Gene Ther."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1073\/pnas.81.4.1189","article-title":"X. chromosome-linked muscular dystrophy (mdx) in the mouse","volume":"81","author":"Bulfield","year":"1984","journal-title":"Proc Natl Acad Sci USA."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/sj.mt.6300161","article-title":"Sustained AAV-mediated dystrophin expression in a canine model of duchenne muscular dystrophy with a brief course of immunosuppression","volume":"15","author":"Wang","year":"2007","journal-title":"Mol Ther."},{"key":"B93","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1089\/hum.2006.093","article-title":"Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of duchenne muscular dystrophy","volume":"18","author":"Wang","year":"2007","journal-title":"Hum Gene Ther."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1038\/mt.2008.207","article-title":"Single intravenous injection of adeno-associated virus serotype-9 leads to whole body skeletal muscle transduction in dogs","volume":"16","author":"Yue","year":"2008","journal-title":"Mol Ther."},{"key":"B95","doi-asserted-by":"publisher","first-page":"5880","DOI":"10.1093\/hmg\/ddv310","article-title":"Safe and bodywide muscle transduction in young adult Duchenne muscular dystrophy dogs with adeno-associated virus","volume":"24","author":"Yue","year":"2015","journal-title":"Hum Mol Genet."},{"key":"B96","doi-asserted-by":"publisher","first-page":"16105","DOI":"10.1038\/ncomms16105","article-title":"Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy","volume":"8","author":"Le Guiner","year":"2017","journal-title":"Nat Commun."},{"key":"B97","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/mt.2009.254","article-title":"Persistent expression of FLAG-tagged micro dystrophin in nonhuman primates following intramuscular and vascular delivery","volume":"18","author":"Rodino-Klapac","year":"2010","journal-title":"Mol Ther."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1056\/NEJMoa1000228","article-title":"Dystrophin immunity in duchenne's muscular dystrophy","volume":"363","author":"Mendell","year":"2010","journal-title":"N Engl J Med."},{"key":"B99","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/mt.2011.237","article-title":"Phase 1 gene therapy for duchenne muscular dystrophy using a translational optimized AAV vector","volume":"20","author":"Bowles","year":"2012","journal-title":"Mol Ther."},{"key":"B100","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/sj.mt.6300027","article-title":"Design of tissue-specific regulatory cassettes for high-level rAAV-mediated expression in skeletal and cardiac muscle","volume":"15","author":"Salva","year":"2007","journal-title":"Mol Ther."},{"key":"B101","volume-title":"Solid Biosciences Provides SGT-001 Program Update","year":""},{"key":"B102","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/00005072-199303000-00004","article-title":"Localization and quantitation of the chromosome 6-encoded dystrophin-related protein in normal and pathological human muscle","volume":"52","author":"Karpati","year":"1993","journal-title":"J Neuropathol Exp Neurol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1089\/10430349950017987","article-title":"Adenovirus-mediated utrophin gene transfer mitigates the dystrophic phenotype of mdx mouse muscles","volume":"10","author":"Gilbert","year":"1999","journal-title":"Hum Gene Ther."},{"key":"B104","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1038\/mt.2008.149","article-title":"Microutrophin delivery through rAAV6 increases lifespan and improves muscle function in dystrophic dystrophin\/utrophin-deficient mice","volume":"16","author":"Odom","year":"2008","journal-title":"Mol Ther."},{"key":"B105","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/360591a0","article-title":"Primary structure of dystrophin-related protein","volume":"360","author":"Tinsley","year":"1992","journal-title":"Nature."},{"key":"B106","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1093\/hmg\/ddp539","article-title":"The artificial gene Jazz, a transcriptional regulator of utrophin, corrects the dystrophic pathology in mdx mice","volume":"19","author":"Di Certo","year":"2010","journal-title":"Hum Mol Genet."},{"key":"B107","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.bbadis.2018.01.030","article-title":"Utrophin up-regulation by artificial transcription factors induces muscle rescue and impacts the neuromuscular junction in mdx mice","volume":"1864","author":"Pisani","year":"2018","journal-title":"Biochim Biophys Acta Mol Basis Dis."},{"key":"B108","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1006\/dbio.2001.0530","article-title":"Overexpression of the CT GalNAc transferase in skeletal muscle alters myofiber growth, neuromuscular structure, and laminin expression","volume":"242","author":"Xia","year":"2002","journal-title":"Dev Biol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/mt.2013.246","article-title":"Vascular delivery of rAAVrh74MCKGALGT2 to the gastrocnemius muscle of the rhesus macaque stimulates the expression of dystrophin and laminin \u03b12 surrogates","volume":"22","author":"Chicoine","year":"2014","journal-title":"Mol Ther."},{"key":"B110","doi-asserted-by":"publisher","first-page":"6ra15","DOI":"10.1126\/scitranslmed.3000112","article-title":"Follistatin gene delivery enhances muscle growth and strength in nonhuman primates","volume":"1","author":"Kota","year":"2009","journal-title":"Sci Transl Med."},{"key":"B111","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","article-title":"Emerging issues in AAV-mediated in vivo gene therapy","volume":"8","author":"Colella","year":"2018","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B112","doi-asserted-by":"publisher","first-page":"7689","DOI":"10.1128\/jvi.77.13.7689-7695.2003","article-title":"Episomal persistence of recombinant adenoviral vector genomes during the cell cycle in vivo","volume":"77","author":"Ehrhardt","year":"2003","journal-title":"J Virol"},{"key":"B113","doi-asserted-by":"publisher","first-page":"6969","DOI":"10.1128\/JVI.75.15.6969-6976.2001","article-title":"Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo","volume":"75","author":"Nakai","year":"2001","journal-title":"J Virol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1073\/pnas.96.5.2296","article-title":"Neonatal gene transfer leads to widespread correction of pathology in a murine model of lysosomal storage disease","volume":"96","author":"Daly","year":"1999","journal-title":"Proc Natl Acad Sci USA."},{"key":"B115","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/ng0797-270","article-title":"Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors","volume":"16","author":"Snyder","year":"1997","journal-title":"Nat Genet."},{"key":"B116","doi-asserted-by":"publisher","first-page":"6916","DOI":"10.1073\/pnas.94.13.6916","article-title":"Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus","volume":"94","author":"Flannery","year":"1997","journal-title":"Proc Natl Acad Sci USA."},{"key":"B117","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1073\/pnas.94.4.1426","article-title":"Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors","volume":"94","author":"Koeberl","year":"1997","journal-title":"Proc Natl Acad Sci USA."},{"key":"B118","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/0006-8993(95)01488-8","article-title":"Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector","volume":"713","author":"McCown","year":"1996","journal-title":"Brain Res."},{"key":"B119","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1089\/10430349950019219","article-title":"Neonatal intramuscular injection with recombinant adeno-associated virus results in prolonged beta-glucuronidase expression in situ and correction of liver pathology in mucopolysaccharidosis type VII mice","volume":"10","author":"Daly","year":"1999","journal-title":"Hum Gene Ther."},{"key":"B120","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/mt.2010.274","article-title":"Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins","volume":"19","author":"Nathwani","year":"2011","journal-title":"Mol Ther."},{"key":"B121","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1182\/blood-2008-10-181479","article-title":"Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy","volume":"113","author":"Niemeyer","year":"2009","journal-title":"Blood."},{"key":"B122","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N Engl J Med."},{"key":"B123","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia B gene therapy with a high-specific-activity factor IX variant","volume":"377","author":"George","year":"2017","journal-title":"N Engl J Med."},{"key":"B124","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1038\/mt.2011.154","article-title":"AAV-microdystrophin therapy improves cardiac performance in aged female mdx mice","volume":"19","author":"Bostick","year":"2011","journal-title":"Mol Ther."},{"key":"B125","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.yjmcc.2012.05.002","article-title":"AAV micro-dystrophin gene therapy alleviates stress-induced cardiac death but not myocardial fibrosis in >21-m-old mdx mice, an end-stage model of Duchenne muscular dystrophy cardiomyopathy","volume":"53","author":"Bostick","year":"2012","journal-title":"J Mol Cell Cardiol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/mt.2008.28","article-title":"Systemic microdystrophin gene delivery improves skeletal muscle structure and function in old dystrophic mdx mice","volume":"16","author":"Gregorevic","year":"2008","journal-title":"Mol Ther."},{"key":"B127","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1089\/hum.2019.255","article-title":"Rodino-Klapac LR. Dose-escalation study of systemically delivered rAAVrh74MHCK7micro-dystrophin in the mdx mouse model of duchenne muscular dystrophy","volume":"32","author":"Potter","year":"2021","journal-title":"Hum Gene Ther."},{"key":"B128","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1038\/sj.gt.3301829","article-title":"Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product","volume":"9","author":"Yuasa","year":"2002","journal-title":"Gene Ther."},{"key":"B129","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1002\/mus.25658","article-title":"Long-term effects of systemic gene therapy in a canine model of myotubular myopathy","volume":"56","author":"Elverman","year":"2017","journal-title":"Muscle Nerve."},{"key":"B130","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1038\/mt.2012.181","article-title":"Muscle function recovery in golden retriever muscular dystrophy after AAV1-U7 exon skipping","volume":"20","author":"Vulin","year":"2012","journal-title":"Mol Ther."},{"key":"B131","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.omtm.2020.04.025","article-title":"Long-term efficacy of AAV9-U7snRNA-mediated exon 51 skipping in mdx52 mice","volume":"17","author":"Aupy","year":"2020","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B132","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1089\/humc.2015.068","article-title":"Evaluation of readministration of a recombinant adeno-associated virus vector expressing acid alpha-glucosidase in pompe disease: preclinical to clinical planning","volume":"26","author":"Corti","year":"2015","journal-title":"Hum Gene Ther Clin Dev."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.814174\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T07:57:17Z","timestamp":1641369437000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.814174\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,5]]},"references-count":132,"alternative-id":["10.3389\/fneur.2021.814174"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.814174","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,5]]},"article-number":"814174"}}